Eli Lilly GLP 1 Rally Still Has Years Left, Analysts Say

Eli Lilly just posted a massive quarter, and top analysts believe the pharmaceutical giant has years of strong growth ahead. During a recent segment on Mad Money, Jim Cramer and analyst Jeff Marks pointed to Eli Lilly and Nvidia as prime examples of momentum stocks that require a long term investment horizon. Marks specifically noted that investors need to look toward the end of the decade, which is when GLP 1 sales will truly peak.

The company delivered second quarter revenue of $23 billion, marking a 48 percent jump compared to the same period last year. A massive 60 percent increase in sales volume helped offset lower realized prices. Because of this momentum, management raised full year revenue guidance to a range of $85 billion to $87 billion, driven by surging sales for treatments like Mounjaro and Zepbound.

Global demand for these treatments is expanding rapidly, especially outside the United States where international revenue jumped 80 percent. While lower prices in regions like China compressed near term margins, they opened access for millions of new patients. Industry projections estimate the global obesity and diabetes drug market will nearly double by 2035, reaching $190 billion.

Traders looking at traditional momentum assets should keep an eye on how upcoming oral treatments and expanding insurance coverage shape the pharmaceutical sector. While this stock operates outside the digital asset space, major multi year trends often influence broader market sentiment and risk appetite across all trading desks.